Market Overview

Canaccord Genuity Reiterates Buy Rating, $100 PT on Watson Pharmaceuticals


In a report published Monday, Canaccord Genuity reiterated its Buy rating and $100.00 price target on Watson Pharmaceuticals (NYSE: WPI).

Canaccord Genuity noted, “It was announced this morning that Mallinckrodt (subsidiary of Covidien) has received FDA approval for the 27, 36 and 54 mg dosage strengths of Concerta ER (~80% of total generic scripts – 18 mg is other ~20%). Mallinckrodt will launch the 27 mg immediately and plans to have the 36 and 54 mg available sometime in calendar Q1 of 2013. Mallinckrodt plans to file on the 18 mg in Q1 of 2013, though approval is likely some time out. While the financial impact to WPI is more limited (a Kudco approval had been factored into guidance and most Street EPS), the Mallinckrodt approval is a surprise and removes a potential sizeable upside driver to 2013 (limited or no competition).”

Watson Pharmaceuticals closed on Friday at $86.10.

Latest Ratings for WPI

Jan 2013DowngradesBuyNeutral
Nov 2012MaintainsOutperform
Nov 2012UpgradesNeutralOverweight

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings


Related Articles (WPI)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Oil & Gasoline Markets End 2012 with Swollen Inventory Levels

UPDATE: Citigroup Maintains Magellan Health Services at Buy Post Contract Loss